Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 8 (August)

1. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
   Mol Cell Biol, 26(16): 6082-93. [Abstract] [Full-text]
2. Herb-drug interactions in oncology: focus on mechanisms of induction.
   Oncologist, 11(7): 742-52. [Abstract] [Full-text]
3. Case histories, magic bullets and the state of drug discovery.
   Nat Rev Drug Discov, 5(8): 635-40. [Abstract] [Full-text]
4. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
   Laryngoscope, 116(8): 1409-16. [Abstract] [Full-text]
5. Gleevec suppresses p63 expression in head and neck squamous cell carcinoma despite p63 activation by DNA-damaging agents.
   Laryngoscope, 116(8): 1390-6. [Abstract] [Full-text]
6. Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases.
   Bioinformatics, 22(15): 1846-54. [Abstract] [Full-text]
7. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
   Blood, 108(4): 1421-3. [Abstract] [Full-text]
8. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
   Blood, 108(4): 1374-6. [Abstract] [Full-text]
9. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.
   Blood, 108(4): 1370-3. [Abstract] [Full-text]
10. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
    Blood, 108(4): 1328-33. [Abstract] [Full-text]
11. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
    Blood, 108(4): 1353-62. [Abstract] [Full-text]
12. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
    Nat Med, 12(8): 908-16. [Abstract] [Full-text]
13. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
    Clin Pharmacol Ther, 80(2): 192-201. [Abstract] [Full-text]
14. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.
    Cancer Chemother Pharmacol, 58(5): 716-8. [Abstract] [Full-text]
15. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
    Oncogene, 25(35): 4913-22. [Abstract] [Full-text]
16. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Cancer, 107(2): 345-51. [Abstract] [Full-text]
17. Treating imatinib-resistant leukemia: the next generation targeted therapies.
    ScientificWorldJournal, 6: 918-30. [Abstract] [Full-text]
18. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Clin Cancer Res, 12(16): 4899-907. [Abstract] [Full-text]
19. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
    Cancer Sci, 97(9): 952-60. [Abstract] [Full-text]
20. Identification of c-Kit gene mutations in patients with polycythemia vera.
    Leuk Res, 30(10): 1325-6. [Abstract] [Full-text]
21. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
    Leuk Res, 30(10): 1263-72. [Abstract] [Full-text]
22. Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia.
    Leuk Res, 30(10): 1273-8. [Abstract] [Full-text]
23. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules.
    Leuk Res, 30(10): 1293-8. [Abstract] [Full-text]
24. Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia.
    Leuk Res, 30(10): 1249-52. [Abstract] [Full-text]
25. Kit expression in spindle cell rhabdomyosarcoma can possibly create a different approach for its tumorigenesis and therapy.
    Pathol Res Pract, 202(9): 671-7. [Abstract] [Full-text]
26. Deletion of chromosome 13: A rare form of cytogenetic evolution in blast phase of chronic myelogenous leukemia Is there an association with favorable outcome?
    Leuk Res. [Abstract] [Full-text]
27. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Blood, 108(5): 1469-77. [Abstract] [Full-text]
28. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
    Blood, 108(5): 1478-84. [Abstract] [Full-text]
29. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.
    Blood, 108(5): 1716-23. [Abstract] [Full-text]
30. Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations.
    Mod Pathol, 19(9): 1157-63. [Abstract] [Full-text]
31. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.
    Leukemia, 20(9): 1526-32. [Abstract] [Full-text]
32. Gene expression signatures associated with the resistance to imatinib.
    Leukemia, 20(9): 1542-50. [Abstract] [Full-text]
33. Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation.
    Int J Hematol, 84(2): 170-3. [Abstract] [Full-text]
34. Constitutional pericentric inversion of chromosome 9 and hematopoietic recovery after allogeneic stem cell transplantation.
    Ann Hematol, 85(9): 611-5. [Abstract] [Full-text]
35. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
    Genes Chromosomes Cancer, 45(10): 950-6. [Abstract] [Full-text]
36. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
    Pediatr Blood Cancer, 47(5): 555-9. [Abstract] [Full-text]
37. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
    Cancer, 107(5): 1008-13. [Abstract] [Full-text]
38. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
    Proc Natl Acad Sci U S A, 103(34): 12843-8. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.